Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Given Average Rating of “Moderate Buy” by Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been given an average rating of “Moderate Buy” by the eleven analysts that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $41.25.

AGIO has been the topic of several recent analyst reports. Weiss Ratings reiterated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Wednesday, June 24th. Truist Financial dropped their price objective on Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating for the company in a report on Friday, July 31st. TD Cowen raised Agios Pharmaceuticals to a “strong-buy” rating in a research report on Monday. Citigroup increased their target price on Agios Pharmaceuticals from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. lifted their target price on Agios Pharmaceuticals from $31.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th.

Agios Pharmaceuticals Stock Up 0.9%

AGIO stock opened at $34.28 on Friday. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of -4.89 and a beta of 0.58. The firm’s fifty day simple moving average is $35.91 and its two-hundred day simple moving average is $31.62.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.65) by ($0.04). The firm had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative return on equity of 35.67% and a negative net margin of 418.24%. As a group, equities research analysts expect that Agios Pharmaceuticals will post -5.82 EPS for the current year.

Insider Buying and Selling

In related news, insider Sarah Gheuens sold 30,000 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $30.48, for a total transaction of $914,400.00. Following the completion of the sale, the insider owned 54,645 shares in the company, valued at $1,665,579.60. This trade represents a 35.44% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in AGIO. Nykredit A S purchased a new position in shares of Agios Pharmaceuticals during the second quarter worth approximately $26,000. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $25,000. Quantbot Technologies LP bought a new position in Agios Pharmaceuticals in the second quarter worth approximately $43,000. NewEdge Advisors LLC bought a new position in Agios Pharmaceuticals in the first quarter worth approximately $40,000. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Agios Pharmaceuticals during the 4th quarter worth $49,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.